SURFAXIN® (lucinactant) Intratracheal Suspension is approved by the U.S. Food and Drug Administration (FDA) for the prevention of respiratory distress syndrome (RDS) in premature infants at high risk for developing RDS.

IMPORTANT SAFETY INFORMATION

SURFAXIN® (Lucinactant) Intratracheal Suspension is intended for intratracheal use only. The administration of exogenous surfactants, including SURFAXIN, can rapidly affect oxygenation and lung compliance: SURFAXIN should be administered only by clinicians trained and experienced with intubation, ventilator management, and general care of premature infants in a highly supervised clinical setting. Infants receiving SURFAXIN should receive frequent clinical assessments so that oxygen and ventilatory support can be modified to respond to changes in respiratory status.

Most common adverse reactions associated with the use of SURFAXIN are endotracheal tube reflux, pallor, endotracheal tube obstruction, and need for dose interruption. During SURFAXIN administration, if bradycardia, oxygen desaturation, endotracheal tube reflux, or airway obstruction occurs, administration should be interrupted and the infant's clinical condition assessed and stabilized.

SURFAXIN® is not indicated for use in acute respiratory distress syndrome (ARDS).

For more information about SURFAXIN, please see full prescribing information.
Concerns About Animal-Derived Products

**Neonatologists**

- 92% expressed concerns over exposure of newborn infants to animal-derived medicines
- 8% expressed concerns over exposure of newborn infants to animal-derived medicines

**Parents of Infants in the NICU**

- 67% want to be informed if an animal-derived medicine is to be administered to their newborn
- 33% want to be informed if an animal-derived medicine is to be administered to their newborn

---


---

**Surfaxin®**

Surfaxin (surfactant) is indicated for intratracheal use only. The administration of Surfaxin should be attended by medical personnel who are trained and experienced in the use of this product. The administration of Surfaxin should be performed by trained personnel experienced in the use of this product.

Surfaxin is not indicated for use in acute respiratory distress syndrome (ARDS).

For more information about Surfaxin, please see full prescribing information.
Comparison of SP-B or SP-B mimic (KL2) as a Percent of Phospholipid Across Commercially Available Surfactants

<table>
<thead>
<tr>
<th>Surfactant</th>
<th>Percentage of Phospholipids</th>
</tr>
</thead>
<tbody>
<tr>
<td>Consort®</td>
<td>0.59</td>
</tr>
<tr>
<td>Intersurf®</td>
<td>0.74</td>
</tr>
<tr>
<td>Survanta®</td>
<td>0.04</td>
</tr>
<tr>
<td>SURFAXIN®</td>
<td>2.87</td>
</tr>
<tr>
<td>Human Surfactant</td>
<td>2.00</td>
</tr>
</tbody>
</table>

5SURFAXIN® (human) Intratracheal Suspension (prescribing information). Warrington, PA: Discovery Laboratories Inc 2012.

Dealing with Respiratory Distress

**IMPORTANT SAFETY INFORMATION**

SURFAXIN® (human) Intratracheal Suspension is indicated for intratracheal use only. The administration of exogenous surfactants, including SURFAXIN, can result in changes in lung compliance. SURFAXIN should be administered only by clinicians trained and experienced with intubation, ventilation management, and general care of premature infants in a highly specialized clinical setting. Infants receiving SURFAXIN should receive frequent clinical assessments to monitor oxygen and ventilatory support can be modified to respond to changes in respiratory status.

Most common adverse reactions associated with the use of SURFAXIN are endotracheal tube reflux, patent endotracheal tube obstruction, and need for dose interruption. During SURFAXIN administration, if bradycardia, oxygen desaturations, endotracheal tube reflux, or airway obstruction occurs, administration should be interrupted and the infant’s clinical condition assessed and stabilized.

SURFAXIN is not indicated for use in acute respiratory distress syndrome (ARDS).

For more information about SURFAXIN, please see full prescribing information.
Unlike animal-derived surfactants that are made with surfactant proteins extracted from animal lung, SURFAXIN® is a synthetic, peptide-containing surfactant manufactured to ensure a consistent level of SP-B mimic (KLB) is delivered with each recommended dose (1).

1. SURFAXIN® (Inginx@) Intraotracheal Suspension [prescribing information]. Waltham, MA: Discovery Laboratories Inc; 2012.